Japanese Regulators Enforcing More Post-Market Surveillance (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
TOKYO - As Japan looks to resolve its drug lag with the West, pharmaceutical companies are finding more and more "all cases surveillance" requirements added as conditions for approval by Japan's Ministry of Health, Labor and Welfare